CervoMed to Present 32-Week Extension Phase Results for Neflamapimod Trial Today

CervoMed will report results from the 32-week extension phase of its Phase 2b RewinD-LB study, which assessed the investigational drug Neflamapimod for dementia with Lewy bodies. The previous topline data did not meet statistical significance for primary and key secondary endpoints, but the extension phase showed improvement in primary outcome measures and a lower incidence of falls. The study involved 149 patients who completed the RewinD-LB study and received Neflamapimod.

CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company specializing in age-related neurologic disorders, will present new data from the 32-week extension phase of its Phase 2b RewinD-LB study on Monday, July 28, 2025, at 8:00 AM ET. The conference call and webcast will follow late-breaking presentations at the Alzheimer's Association International Conference 2025.

The RewinD-LB study evaluated oral neflamapimod, an investigational small molecule that inhibits p38 mitogen-activated protein kinase alpha, in patients with dementia with Lewy bodies (DLB). The study excluded patients with Alzheimer’s disease co-pathology, focusing on “pure” DLB patients who may comprise up to 50% of the diagnosed DLB patient population.

The primary outcome measure was change in the Clinical Dementia Rating – Sum of Boxes, with secondary endpoints including Alzheimer's Disease Cooperative Study - CGIC, the Timed Up and Go test, and a cognitive test battery. The extension phase involved 149 patients who completed the initial 16-week phase and received neflamapimod for an additional 32 weeks.

The study is funded primarily by a $21.3 million grant from the National Institutes of Health’s National Institute on Aging. The results from the extension phase are anticipated to provide insights into the efficacy and safety of neflamapimod in DLB patients.

The previous topline data from the initial phase did not meet statistical significance for primary and key secondary endpoints, but the extension phase showed improvement in primary outcome measures and a lower incidence of falls. This could indicate potential benefits of neflamapimod in treating DLB.

CervoMed's shares have surged nearly 250% over the past six months, reflecting investor optimism about the company's research and development efforts. The company maintains a strong liquidity position with a current ratio of 9.78 and a cash position of $35.2 million as of the first quarter of 2025.

Investors and financial professionals are encouraged to attend the conference call and webcast to gain a deeper understanding of the latest findings from the RewinD-LB study.

References:
[1] https://ir.cervomed.com/news-releases/news-release-details/cervomed-present-new-data-phase-2b-rewind-lb-study-aaic-2025-and
[2] https://www.investing.com/news/company-news/cervomed-to-report-32week-extension-phase-results-for-dlb-treatment-93CH-4152341
[3] https://www.biospace.com/press-releases/cervomed-to-present-new-data-from-phase-2b-rewind-lb-study-at-aaic-2025-and-host-conference-call-on-july-28-2025